Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP588844.RAh1St2N8yD3tQUxogkvQJwfUvT8Cqd8jBw-1qed5PJGI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP588844.RAh1St2N8yD3tQUxogkvQJwfUvT8Cqd8jBw-1qed5PJGI130_assertion type Assertion NP588844.RAh1St2N8yD3tQUxogkvQJwfUvT8Cqd8jBw-1qed5PJGI130_head.
- NP588844.RAh1St2N8yD3tQUxogkvQJwfUvT8Cqd8jBw-1qed5PJGI130_assertion description "[Evidence from pooled data for genetic association with tardive dyskinesia (TD) showed (1) in COMT(val158met), using Val-Val homozygotes as reference category, a protective effect for Val-Met heterozygotes (OR=0.63, 95% CI: 0.46-0.86, P=0.004) and Met carriers (OR=0.66, 95% CI: 0.49-0.88, P=0.005); (2) in Taq1A in DRD2, using the A1 variant as reference category, a risk-increasing effect for the A2 variant (OR=1.30, 95% CI: 1.03-1.65, P=0.026), and A2-A2 homozygotes using A1-A1 as reference category (OR=1.80, 95% CI: 1.03-3.15, P=0.037); (3) in MnSOD Ala-9Val, using Ala-Ala homozygotes as reference category, a protective effect for Ala-Val (OR=0.37, 95% CI: 0.17-0.79, P=0.009) and for Val carriers (OR=0.49, 95% CI: 0.24-1.00, P=0.047).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP588844.RAh1St2N8yD3tQUxogkvQJwfUvT8Cqd8jBw-1qed5PJGI130_provenance.
- NP588844.RAh1St2N8yD3tQUxogkvQJwfUvT8Cqd8jBw-1qed5PJGI130_assertion evidence source_evidence_literature NP588844.RAh1St2N8yD3tQUxogkvQJwfUvT8Cqd8jBw-1qed5PJGI130_provenance.
- NP588844.RAh1St2N8yD3tQUxogkvQJwfUvT8Cqd8jBw-1qed5PJGI130_assertion SIO_000772 18180754 NP588844.RAh1St2N8yD3tQUxogkvQJwfUvT8Cqd8jBw-1qed5PJGI130_provenance.
- NP588844.RAh1St2N8yD3tQUxogkvQJwfUvT8Cqd8jBw-1qed5PJGI130_assertion wasDerivedFrom befree-20140225 NP588844.RAh1St2N8yD3tQUxogkvQJwfUvT8Cqd8jBw-1qed5PJGI130_provenance.
- NP588844.RAh1St2N8yD3tQUxogkvQJwfUvT8Cqd8jBw-1qed5PJGI130_assertion wasGeneratedBy ECO_0000203 NP588844.RAh1St2N8yD3tQUxogkvQJwfUvT8Cqd8jBw-1qed5PJGI130_provenance.